Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Completed Trials

LUD 2015-005: ANTI-PD-L1 in combination with chemo(radio)therapy for oesophageal cancer

SCALOP-2: Systemic therapy and Chemoradiation in Advanced Localised Pancreatic cancer–2

CHARIOT: M6620 plus standard treatment in oesophageal and other cancer

CYTOFLOC: Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer

FRONTIER: Fluciclovine (18F) imaging of breast cancer

FRONTIER: An open-labelled study to characterise Fluciclovine (18F) uptake measured by positron emission tomography in breast cancer

NuTide:301: Safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.

IMAGO: A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI

TARDOX: Targeted chemotherapy using focused ultrasound for liver tumours

TARDOX :A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours

CAMELLIA: Anti-CD47 antibody terapy in relapsed/refractory Haematological Malignancies

CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia

ATOM: Atovaquone as Tumour HypOxia Modifier

ATOM: Pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma.